NASDAQ · ECOR
Healthcare · Medical - Devices
$10.52
Up+$0.31 (+3.04%)
Updated Aug 23, 2026, 12:13 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ECOR closed at $10.52 after 20 trading sessions, up 73.88% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $10.33 | $10.95 | $10.00 | $10.52 | 59.94K |
| Aug 20, 2026 | $10.70 | $10.81 | $9.64 | $10.21 | 182.66K |
| Aug 19, 2026 | $10.35 | $10.93 | $9.8501 | $10.81 | 74.45K |
| Aug 18, 2026 | $10.26 | $10.54 | $10.02 | $10.27 | 47.23K |
| Aug 17, 2026 | $10.15 | $10.68 | $10.00 | $10.25 | 144.33K |
| Aug 14, 2026 | $9.71 | $10.39 | $9.68 | $9.97 | 119.8K |
| Aug 13, 2026 | $9.53 | $10.05 | $8.74 | $9.94 | 109.37K |
| Aug 12, 2026 | $9.00 | $9.50 | $8.72 | $9.40 | 81.16K |
| Aug 11, 2026 | $8.79 | $9.37 | $8.66 | $9.12 | 76.56K |
| Aug 10, 2026 | $8.02 | $8.99 | $7.6771 | $8.96 | 51.68K |
| Aug 7, 2026 | $6.70 | $8.82 | $6.35 | $8.09 | 214.32K |
| Aug 6, 2026 | $6.355 | $6.71 | $5.8001 | $6.70 | 203.9K |
| Aug 5, 2026 | $6.36 | $6.56 | $6.10 | $6.53 | 25.89K |
| Aug 4, 2026 | $6.00 | $6.68 | $6.00 | $6.23 | 197.91K |
| Aug 3, 2026 | $6.03 | $6.325 | $5.74 | $6.09 | 144.03K |
| Jul 31, 2026 | $6.24 | $6.33 | $5.98 | $6.085 | 37.06K |
| Jul 30, 2026 | $6.14 | $6.605 | $6.01 | $6.29 | 59.41K |
| Jul 29, 2026 | $6.10 | $6.38 | $5.97 | $6.07 | 56.12K |
| Jul 28, 2026 | $6.02 | $6.42 | $6.00 | $6.09 | 25.13K |
| Jul 27, 2026 | $6.27 | $6.42 | $5.88 | $6.05 | 31.46K |
The latest Smart Investors Daily articles mentioning ECOR.
ECOR research
Company profile and research snapshot.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 26, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2025 | Ladenburg Thalmann | Buy | — |
| Mar 13, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 18, 2024 | HC Wainwright & Co. | Buy | — |
| Mar 14, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 7, 2026
electroCore (NASDAQ:ECOR) reported second-quarter 2026 revenue of $9.5 million, up approximately 28% from $7.4 million a year earlier, as growth in Veterans Affairs prescription sales and direct-to-consumer Truvaga sales lifted results. The company raised its full-year revenue outlook to growth of m
SeekingAlpha · Aug 6, 2026
electroCore, Inc. (ECOR) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsThomas Errico - Founder & Independent ChairmanJoshua Lev -...
Benzinga · Aug 6, 2026
electroCore (NASDAQ:ECOR) lowers FY2026 sales outlook from $41.642 million to $41.600 million vs $41.921 million estimate.
Benzinga · Aug 6, 2026
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.40) by 17.5 percent. This is a 25 percent increase over losses of $(0.44) per share from the same
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ECOR.
